-
HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEN WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY USING REAL-WORLD DATA
Feb 25, 2026, 14:40 PM -
FINANCIAL COSTS OF PROVIDING ORAL PRE- AND POST-EXPOSURE PROPHYLAXIS VIA PHARMACIES IN KENYA
Feb 25, 2026, 14:40 PM -
EASE OF USE OF TIRZEPATIDE: RESULTS FROM A US SURVEY OF INDIVIDUALS WITH OBESITY OR OVERWEIGHT
Feb 25, 2026, 14:40 PM -
BEYOND SURVIVAL: HOW NON-HODGKIN LYMPHOMA IMPACTS WELL-BEING AND FINANCES COMPARED TO OTHER CANCERS
Feb 25, 2026, 14:40 PM -
TRENDS IN MORTALITY RELATED TO CIRRHOSIS IN COLOMBIA 2000 - 2024
Feb 25, 2026, 14:40 PM -
COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS
Feb 25, 2026, 14:40 PM -
COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN
Feb 25, 2026, 14:40 PM -
IMPACT OF GLP-1 RECEPTOR AGONIST (GLP-1 RAS) PERSISTENCE VERSUS DISCONTINUATION ON CARDIOMETABOLIC MEASURES IN POLYCYSTIC OVARY SYNDROME (PCOS) OVER A TWO-YEAR FOLLOW-UP
Feb 25, 2026, 14:40 PM -
DISPARITIES BY SOCIOECONOMIC STATUS IN TIME FROM DIAGNOSIS TO CURATIVE SURGICAL TREATMENT FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER IN U.S. ADULTS
Feb 25, 2026, 14:40 PM -
PREDICTING TREATMENT-RESISTANT DEPRESSION AMONG MEDICARE BENEFICIARIES USING MACHINE LEARNING
Feb 25, 2026, 14:40 PM -
REAL WORLD EVIDENCE FOR DOSE-RESPONSE RELATIONSHIP BETWEEN WEIGHT LOSS AND CLINICAL OUTCOMES IN OBESITY RELATED COMORBIDITIES
Feb 25, 2026, 14:40 PM -
PREFERENCES FOR LONG-ACTING PREP ADMINISTRATION AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES
Feb 25, 2026, 14:40 PM -
INCREMENTAL DIRECT AND INDIRECT COSTS OF SJOGREN'S DISEASE IN THE UNITED STATES: A RETROSPECTIVE ANALYSIS USING MARKETSCAN DATABASES
Feb 25, 2026, 14:40 PM -
HIV LIFETIME AND ANNUAL COSTS IN BRAZIL
Feb 25, 2026, 14:40 PM -
MIND THE MORTALITY GAP: COMPARING AVERAGE AND AGE-DISTRIBUTION APPROACHES TO ESTIMATING BACKGROUND SURVIVAL FOR HEALTH ECONOMIC MODELS
Feb 25, 2026, 14:40 PM -
MODEL-BASED COST-UTILITY ANALYSIS OF RECENTLY APPROVED THERAPIES USING RECONSTRUCTED RANDOMIZED CONTROLLED TRIAL OUTCOMES
Feb 25, 2026, 14:40 PM -
A COMPREHENSIVE GLOBAL SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE OF RELAPSED/REFRACTORY AND POST-BRUTON TYROSINE KINASE INHIBITOR MANTLE CELL LYMPHOMA
Feb 25, 2026, 14:40 PM -
COST-EFFECTIVENESS OF INTENSIVE VERSUS STANDARD HYPERTENSIVE THERAPY AMONG TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION
Feb 25, 2026, 14:40 PM -
AI-ASSISTED RISK OF BIAS ASSESSMENT IN OBSERVATIONAL STUDIES: ISOLATING JUDGMENT USING A PASSAGE-BASED VALIDATION APPROACH
Feb 25, 2026, 14:40 PM -
DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN AFTER ISCHEMIC STROKE IN PATIETS WITH ATRIAL FIBRILLATION: A POPULATION-BASED STUDY FROM BRAZIL
Feb 25, 2026, 14:40 PM
